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A B S T R A C T
Hypoxia is common occurrence of the tumour microenvironment, wherein heterogeneous gradients of O2 give
rise to tumoural cells which are highly malignant, metastatic, and resistant to therapeutic efforts. Thus, the
assessment and imaging of hypoxia is essential for tumour diagnosis and treatment. Magnetic resonance imaging
and, more specifically, the quantitative assessment of longitudinal relaxation time enhancement, was shown to
enable the mapping of oxygen in tumours with increased sensitivity for lipids as compared to water signal.
Unfortunately, this can only be applied to tumours with high lipid content. To overcome this issue, we propose
the use of lipid nanocapsules (LNCs). LNCs have been demonstrated as excellent core-shell nanocarriers, wherein
the lipidic-core is used for lipophilic drug encapsulation, enabling treatment of highly malignant tumours.
Herein, however, we exploited the lipidic-core of the LNCs to develop a simple but effective technique to in-
crease the lipidic content within tissues to enable the assessment and mapping of pO2. LNCs were prepared using
the phase-inversion technique to produce 60 nm sized nanoparticles, and in vitro studies demonstrated the
permeability and responsiveness of LNCs to O2. To evaluate the ability of LNCs to respond to changes in pO2 in
vivo, after a hyperoxic challenge, three animal models, namely a normal tissue model (gastrocnemius muscle
tissue) and two tumour tissue models (subcutaneous fibrosarcoma and intracerebral glioblastoma) were ex-
plored. LNCs were found to be responsive to variation of O2 in vivo. Moreover, the use of MRI enabled the
mapping of oxygen gradients and heterogeneity within tumours.
1. Introduction
Hypoxia is a key feature in solid tumours caused by abnormal and
torturous vasculature which are unable to meet the O2 demand of the
tumour mass. This oxygen deprivation causes; a change in gene ex-
pression; leading to more aggressive tumours; and results in metastatic
progression and resistance to radiation and chemotherapy [1,2]. Thus,
a need has risen to combat the poor outcome of treatment interventions
by developing techniques to image and assess the hypoxic tumour
environment. Ideally, the imaging of hypoxia should be non-invasive,
sensitive, robust, quantitative, widely available and able to reflect tu-
mour heterogeneity. To this end, techniques such as electron para-
magnetic resonance and positron emission tomography imaging have
been developed, but magnetic resonance imaging (MRI) techniques are
more appealing due to its ability to provide spatial information and its
use of non-ionising probes.
The development of perfluorinated compounds began the use of 19F-
based MR oximetry and introduced the use of exogenous probes [3–5],
https://doi.org/10.1016/j.msec.2019.03.104
Received 17 October 2018; Received in revised form 1 February 2019; Accepted 28 March 2019
Abbreviations: ATCC, American Type Culture Collection; BW, bandwidth; C3H/HeJ, mouse strain; C6, murine glioblastoma cell line; CED, convection enhanced
delivery; DMEM, Dulbecco modified Eagle medium; FOV, field of view; FSaII, murine fibrosarcoma cell line; IR FISP, inversion-recovery fast imaging with steady
state precession; LNC, lipid nanocapsule; MOBILE, mapping of oxygen by imaging lipids relaxation enhancement; MRI, magnetic resonance imaging; PDI, poly-
dispersity index; PEG, polyethylene glycol; pO2, partial pressure of oxygen; R1, inverse of longitudinal relaxation rate; RARE, rapid acquisition with refocused echoes;
ROI, region of interest; SD, standard deviation; T1, longitudinal relaxation time; TE, mean echo time; TR, repetition time
⁎ Corresponding author at: Micro et Nanomedecines translationnelles, MINT, UNIV Angers, INSERM 1066, CNRS 6021, 4 rue Larrey, Angers, France.
E-mail address: laurent.lemaire@univ-angers.fr (L. Lemaire).
Materials Science & Engineering C 101 (2019) 396–403
Available online 02 April 2019
0928-4931/ © 2019 Elsevier B.V. All rights reserved.
T
however their in vivo application was limited by the need for specialist
MR equipment regarding the 19F-tuned probe. Endogenous probes, such
as water and lipids, had no such limitation. Regardless the origin of the
sensor, oxygen measurement is based on the change in longitudinal
relaxation time (T1). Indeed, molecular oxygen (O2) possesses two un-
paired electrons which enable its paramagnetic ability to act as a T1-
shortening agent in tissues [6], and therefore as a signal intensity en-
hancer on MR T1-weighted sequences [7]. Therefore, the change of
oxygenation is also directly correlated with the longitudinal relation
rate (1 / T1=R1) [4,8]. Despite being attractive for oxygenation mea-
surements, with respect to the high water content of biological tissues,
water T1 change with oxygen concentration is limited, and lower than
the change observed with lipids, due the six times higher solubility of
oxygen in lipids than in water [9]. This property was exploited by
Jordan and colleagues who developed an MR sequence to map oxygen
based on imaging of lipid relaxation rates (MOBILE; acronym for
mapping of oxygen my imaging of lipid relaxation enhancement) [10].
The drawback of this method however, is that there is not always a
sufficient amount of intrinsic lipids in the tissue of interest to enable the
use of the MOBILE method. This limitation can be overcome by the use
of lipid nanocapsules (LNCs) [11]: a nanocarrier with an oil-filled core
surrounded by a protective polymer shell, capable of encapsulating
drugs, with proven treatment efficiency in preclinical glioblastoma
cancer models [12–14]. Thus, while delivering therapy, an increase in
lipid level can be reached allowing MR oxygenation mapping using the
described MOBILE method. Notably, LNCs are also of particular interest
due to their O2 permeability [15], solvent free and FDA-approved
constituents, and their ability to avoid the immune system [16]. Using
the MOBILE MR sequence, LNCs were investigated for their ability to
respond to changes in O2 concentrations in vitro. For in vivo experi-
ments, a muscle model and two tumour models were employed to assess
the ability of the LNCs to act as an oxygen sensor during carbogen re-
spiratory challenges.
2. Materials and methods
2.1. Reagents
The lipophilic Labrafac® WL 1349 (caprylic-capric acid triglycer-
ides; European Pharmacopeia, IVth, 2002) was purchased from
Gattefossé S.A. (Saint-Priest, France). Lipoïd S75-3 (soybean lecithin at
69% of phosphatidylcholine) and Kolliphor® HS 15 (a mixture of free
polyethylene glycol 660 and polyethylene glycol 660 hydroxystearate)
were provided by Lipoïd GmbH (Ludwigshafen, Germany) and BASF
(Ludwigshafen, Germany), respectively. NaCl was purchased from
Prolabo (Fontenay-sous-Bois, France). Filtered and deionised water was
obtained from a Milli-Q plus® system (Millipore).
2.2. Formulation and characterisation of LNCs
LNCs were prepared according to the phase inversion method [11].
Briefly, 1.028 g of Labrafac (oil phase), Lipoïd (0.075 g), Kolliphor® HS
15 (0.846 g), NaCl (0.148 g) and water (2.962 g) were mixed and he-
ated to 95 °C with magnetic stirring. Thereafter the mixture underwent
three cycles of cooling and heating between 50 °C and 95 °C. After the
final heating phase, the solution was cooled to 72 °C and subjected to an
irreversible shock induced by adding 1mL of 4 °C water. This fast
cooling allowed for the formation of stable, core-shell LNCs. Thereafter,
the osmolarity of the formulation was adjusted to be physiologically
safe for in vivo administration. To achieve this, 1 mL of the LNC for-
mulation was dialysed using dialysis tubing (Spectra Biotech Cellulose
Ester Dialysis Membrane, MWCO=100 kDa) for 24 h against pure
water (Milli-Q plus® system, Millipore), changing the water hourly for
6 h. Then, to obtain the original volume of LNCs, the dilution factor of
the dialysed solution was calculated and evaporation, using N2, with
magnetic stirring was done. Once the initial volume was obtained,
evaporation was ceased and 30 μL of a salt solution (320mg/mL) was
added. Osmolarity measurements were performed using a 5520 Vapro
vapour osmometer from Wescor (Logan, Utah, USA). Osmolarity ad-
justed LNCs were used for all in vivo experiments. The average hydro-
dynamic size and polydispersity index (PDI) of the LNCs were de-
termined by dynamic light scattering using a Malvern Zetasizer® (Nano
Series DTS 1060, Malvern Instruments S.A., Worcestershire, UK) fitted
with a 633 nm laser beam (helium–neon laser, 4 mW) at a fixed scat-
tered angle of 173°. To ensure accuracy, LNCs were diluted 1:60 (v/v)
in deionised water to produce scattering intensity values that were in
the midrange of the instrument's detector. Values are expressed as mean
of three measurements± standard deviation (SD) for five formulations.
2.3. In vitro sensitivity of LNCs to pO2
To evaluate the response of LNCs to variations in O2, the MOBILE
sequence was applied wherein the T1 of the methylene group
(~1.2 ppm) of the lipid core of the LNCs was measured at 37 °C in
sealed tubes bubbled with nitrogen (0% O2), air (21% O2) or pure
oxygen (100% O2) for 30min with magnetic stirring. Temperature of
the samples was maintained using a warm water circulation system.
MOBILE sequence acquisition parameters were as follows; repetition
time (TR): 1520ms; mean echo time (TE): 0.8ms, flip angle: 5°;
bandwidth (BW): 200 kHz at 30% echo position; matrix: 32×32, field
of view (FOV): 5×5 cm; 16 segments, a series of 50 images spaced at
TR 29.80ms with a slice thickness of 4mm, and a total acquisition time
of approximately 35min. Determination and acquisition of the lipid
signal was adapted from Jordan et al. [10]. Briefly, the difference in
frequency between the water and lipid peaks (i.e. 1.2 ppm for the me-
thylene group of the lipid core of LNCs) in a 1H proton spectrum was
determined and used as the offset for the imaging frequency for the
MOBILE sequence. A Gaussian saturation pulse of 2.74ms with a
1000 Hz frequency range to spoil the water signal was applied.
2.4. Animal model care and preparation
Animal care and use were in accordance with the regulations of the
French Ministry of Agriculture and approved by the Pays de la Loire
Ethics in Animal Experimentation Committee under project number
01858.03. Animals were housed in a controlled and pathogen-free en-
vironment, with free access to food and water, at the University animal
facility (SCAHU-Angers, France). Animal anaesthesia was induced by a
continuous flow of air (0.5–0.8 L/min) and 3% isoflurane (Piramal
Healthcare, UK Limited, Northumberland, UK) and maintained with
0.5–1% isoflurane. Body temperature was maintained during MR ac-
quisition using a heated water circulating system. Respiration was also
monitored. Three animal models were used in this in vivo study; an
intramuscular tissue model and two tumoural tissue models, namely
subcutaneous fibrosarcoma and intracerebral glioblastoma tumours.
2.4.1. Normal gastrocnemius muscle animal model
Five 7-week old male C3H/HeJ mice (Janvier, Le Genest-Saint-Isle,
France) were used for the intramuscular tissue study.
2.4.2. Cell culture for tumoural animal models
Two tumour models were used in this study; a subcutaneous fi-
brosarcoma model and an intracerebral glioblastoma model. Culture
reagents were obtained from Thermo Fisher Scientific, Gibco and
BioWhittaker (France). For the subcutaneous fibrosarcoma model, the
syngenic FSaII fibrosarcoma murine cell line [17] was utilised and
grown in Dulbecco's modified Eagle's medium (DMEM) high glucose
GlutaMAX supplemented with 10% bovine serum and 1% Pen/Strep.
For the intracerebral glioblastoma model, the C6 rat glioma cell line
was purchased from ECACC and was grown in Ham's F12 medium,
supplemented with 1mM L-glutamine, 10% bovine serum and 1% Pen/
Strep. Cells were grown in standard cell culture conditions (21% O2, 5%
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CO2 and 37 °C).
2.4.2.1. Subcutaneous fibrosarcoma tumour model. Seven male 7-week-
old C3H/HeJ mice (Janvier, Le Genest-Saint-Isle, France) were
inoculated subcutaneously into the hind thigh with 2×106 FSaII
cells in 100 μL serum-free DMEM under isoflurane anaesthesia. MR
experiments were undertaken once tumours reached 8–10mm in
diameter.
2.4.2.2. Intracerebral glioblastoma tumour model. Glioblastomas were
induced in the caudate putamen of 10–12week-old female Sprague-
Dawley rats (n=6) (SCAHU-Angers, France) via the stereotaxic
inoculation of C6 rat glioma cells as previously described [18].
Briefly, under Rompun® (Xylazine, Bayer AG, Leverkusen, Germany)
and Clorketam® (Kétamine, Vétoquinol, Lure, France) anaesthesia, rats
were fixed in a stereotaxic holder and placed on a heating pad to
maintain the appropriate physiological temperature. Through a 1mm
drilled hole in the skull (anterior 5mm, lateral 3 mm, depth 7mm in
respect to bregma), a 5 μL suspension of 4.0× 104 C6 rat glioma cells
were injected over a 10min period into the caudate putamen of the
right hemisphere. After surgery, rats received a single 30 μg/kg
subcutaneous injection of Vetergesic® (buprenorphine, Sogeval,
France) for pain management. Animals were monitored daily for
grooming and mobility, and MR experiments commenced when
tumours reached approximately 30 μL in volume.
2.5. MR experiments
MR imaging was performed using a 7 T scanner (Biospec 70/20
Avance III, Bruker Wissembourg, France) equipped with BGA12S gra-
dient system (675mT/m). Emission was ensured by an 86mm diameter
resonator and reception by a 2×2 surface array coil positioned over
the rat head for C6-glioma experiment and or a 2 cm diameter loop coil
positioned under the mouse leg or tumour. For the duration of all MR
experiments, animal temperature was regulated by a heated water-
circulating system. For anatomical images, T2-weighted rapid acquisi-
tion with refocused echoes (RARE) set of images was acquired to follow
the volume of tumours (TR=3200ms; TE=21.3 ms; RARE factor= 4;
FOV=4×4 cm; matrix= 256×256; nine contiguous slices of
0.5 mm, Nex=1). Thus, once tumours were of proper size, the LNC
suspension was injected into the tissue. Animals were anaesthetised,
and a bolus injection of 40 μL was injected intramuscularly in the
normal tissue model, or intratumourally for the subcutaneous fi-
brosarcoma tumour model. For LNC delivery into the intracerebral
glioblastoma tumour model, a convection-enhanced delivery (CED)
protocol [19,20] was implemented to provide a well-diffused distribu-
tion of the 40 μL LNCs in the brain tumour. Once the LNC suspension
was introduced into the animal model, T1 was measured using the
MOBILE MR sequence (with acquisition parameters described in
Section 2.3, with geometry changes for in vivo experiments adjusted as
follows; slice of 3mm, and a FOV=1×1 cm for mice and 3× 3 cm for
rats). LNC T1 sensitivity to oxygen variation in the different animal
models was assessed using a carbogen (95% O2, 5% CO2) breathing
challenge [7].
2.5.1. T1 lipid measurement using MOBILE
The MOBILE sequence, described by Jordan et al. [10] as a seg-
mented inversion-recovery fast imaging with steady state precession (IR
FISP), was used to acquire images in order to calculate T1 relaxation
time maps while the animal was breathing air and carbogen. After the
acquisition of the T1-weighted MOBILE MR image set, the T1 was cal-
culated using a non-linear fit with a home-made program written in
Matlab (The MathWorks, Inc., Natick, MA) for a global value of a
manually drawn region of interest (ROI), and for each pixel within the
same ROI, wherein the magnetisation Mz is a function of the inversion
time (TI), according to: Mz(TI)=A− Bexp(−TI / C); with
A=M0(T1* / T1); B=M0(1+T1* / T1); and C=T1*, and then
T1= (B / A− 1)T1*. The difference between R1 (=1 / T1) during car-
bogen and air breathing for each pixel was calculated and represented
as oxygenation maps.
2.6. Statistical analysis
For the in vivo pO2 measurements, one-tailed Wilcoxon tests were
used to compare the mean changes between groups (air vs. carbogen
breathing within the intramuscular, fibrosarcoma and glioblastoma
groups). Histogram distributions, linear fits and Wilcoxon rank tests
(for pixel-to-pixel analyses) with p values < 0.05 (*) were considered
significant, and were calculated using Prism 5 software.
3. Results
3.1. LNC preparation and characterisation
The phase inversion process was exploited to obtain LNCs consisting
of a lipidic-core (i.e. Labrafac) enclosed within a polymer-based (i.e.
PEG) shell. After osmolarity adjustment, the LNCs had an average size
and PDI of 60.7 ± 0.9 nm and 0.152 ± 0.016, respectively. These
physicochemical properties are comparable to previously studied LNCs
for up to a year [21–23].
3.2. In vitro validation of LNCs sensitivity to oxygen
To assess the ability and sensitivity of the LNCs to probe oxygena-
tion variations in vitro, R1 relaxation rates of the formulation's lipid
component (i.e. Labrafac core) was assessed, in LNCs equilibrated in
different oxygen environments (0%, 21% and 100%) at 37 °C. As shown
in Fig. 1, the R1 of the CH2 backbone of Labrafac is sensitive to oxygen
variation. This is demonstrated by the linear relationship between the
change in oxygen from 0 to 100% and the concurrent increase of R1 by
30% (R2= 0.9948).
3.3. Intramuscular pO2 measurements with LNCs
Following an intramuscular bolus injection of 40 μL of LNCs, a set of
T2-weighted RARE images was acquired to produce an anatomical
image (Fig. 2a), which was used to define the location wherein the
LNCs were deposited. Fig. 2b presents the last image of the MOBILE set,
and shows the lipid deposit. It should be noted that the bright areas of
the MOBILE image in Fig. 2b corresponds to the lipid deposit as well as
to the subcutaneous fat surrounding the muscle tissue, while the dark
areas within the muscle are where no LNCs were introduced. The ab-
sence of signal in the muscle highlights that basal muscular lipid
Fig. 1. In vitro sensitivity of the lipid relaxation rate (R1) arising from lipid
nanocapsules (LNCs) to oxygenation as measured by using the MOBILE MR
sequence (R2=0.9948).
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content is too low to give rise to significant lipid signal. A ROI was
drawn around the lipid hypersignal arising from the LNCs, and was
used to calculate the global R1 for each animal during air or carbogen
breathing. Herein, the carbogen challenge was used to induce a tran-
sient increase in oxygenation within the normal and tumoural tissue, as
previously demonstrated [7,24–26]. In the present study, an increase in
oxygenation was observed through the increase in the global R1 over
the LNC area for all explored mice (Fig. 2c: p= 0.0313, n= 5) with an
overall 6% mean increase. Moreover, a pixel-to-pixel analysis of the
LNC area was also performed. The insert in Fig. 2b shows the R1 change
in the lipid deposit area induced by the carbogen challenge on a pixel-
to-pixel basis with the corresponding ΔR1 distribution histogram shown
in Fig. 2d. For all mice, a median of 61% of pixels responded to the
carbogen challenge and showed an increase in R1. For the mouse pre-
sented in Fig. 2d, the median change in R1 after the carbogen challenge
was calculated at 0.1509 s−1 with 66% of the pixels responding (for all
mice=median change of 0.3450 s−1). For data regarding all in-
dividuals in the intramuscular study, see the Supplementary doc-
umentation (S1).
3.4. Intratumoural pO2 measurements with LNCs
Two tumoural models; the subcutaneous fibrosarcoma and the
intracerebral glioblastoma models were used in this study. These tu-
moural models were chosen to represent two types of severely hypoxic
tissues (pO2 < 10mmHg [26,27]) and their associated heterogeneity,
as well as two different conditions in which LNCs could be administered
into tumours. On the one hand, the subcutaneous fibrosarcoma tumours
which are easily accessible and in which a bolus injection of LNC so-
lution was deposited; and on the other hand, the intracerebral glio-
blastoma tumours in which the LNC solution was infused into the tu-
moural tissue using CED [19,20].
For the subcutaneous fibrosarcoma model, a bolus injection was
performed similarly to the intramuscular model. To verify the correct
targeting of the injection, a T2-weighted anatomical RARE image set
was performed (Fig. 3a), followed by the MOBILE sequence (Fig. 3b). As
with the intramuscular experiments, a ROI was drawn around the lipid
LNC signal in the last image of the MOBILE image set, and was used to
determine the global R1 change after the carbogen challenge for all the
animals. A significant global R1 variation for subcutaneous tumours was
induced by the carbogen challenge (Fig. 3c; p= 0.0452, n=7) with a
3% mean change for the responding animals (6 out of 7). To evaluate
the response to the carbogen challenge more in depth, pixel-to-pixel R1
variation maps illustrating the change in oxygenation was calculated,
and an individual's response is illustrated in Fig. 3b & d. For all mice, a
median of 71% of pixels responded to the carbogen challenge and was
Fig. 2. Application of lipid nanocapsules (LNCs) to assess variations of oxygenation in the intramuscular tissue of mice using lipid relaxation rate measured with the
MOBILE MR sequence, wherein (A) shows the transversal anatomical image of a mouse gastrocnemius muscle and the injected LNCs (indicated by arrow) and (B)
shows the lipid image issued from the set of images acquired with the MOBILE MR sequence wherein the lipids from the LNCs can be observed. The global R1
measured over the entire lipid deposit signal for all mice (n= 5) is shown in (C). The insert in (B) indicates the change in R1 (ΔR1=R1 carbogen – R1 air) for each pixel
of lipid signal in the MOBILE image and a colour scale highlights the more responsive pixels in red (s–1). ΔR1 distribution of all encompassing pixels in the lipid
deposit region of interest is represented as a histogram (D), wherein the median change of R1 is indicated with a dotted red line.
J. Nel, et al. Materials Science & Engineering C 101 (2019) 396–403
399
associated with an increase in R1. For the individual in Fig. 3b & d, the
median change in R1 after the carbogen challenge was calculated at
0.2034 s−1 with 71% of the pixels responding (for all mice=median
change of 0.1779 s−1). Data regarding all individuals in the sub-
cutaneous fibrosarcoma tumour study are presented in the Supple-
mentary documentation (S2).
For the intracerebral glioblastoma tumour model, a CED protocol
was used to introduce the LNCs into the brain tumour and the dis-
tribution of the solution is apparent in the T2-weighted anatomical
RARE image (Fig. 4a). As in the two previous animal models, the
MOBILE MR image (Fig. 4b) was used to draw the global ROI to de-
termine the change in R1. Here, a similar pattern emerges as with the
subcutaneous fibrosarcoma tumours; five out of the six intracerebral
glioblastoma tumours responded with an average of 6% increase in
global R1 (Fig. 4c; p= 0.0313, n=6). Pixel-to-pixel analysis of the
change in global R1 from air to carbogen (Fig. 4b insert) highlights the
response of an individual responding to the carbogen challenge, and all
individuals in the intracerebral glioblastoma study are represented in
the Supplementary documentation (S3). In the intracerebral glio-
blastoma study, a median of 62% of pixels for all animals responded to
the carbogen challenge. For the individual in Fig. 4d, 76% of pixels
responded to the carbogen challenge to produce a median change of
0.2475 s−1 (median change of 0.3187 s−1 for all rats). It should also be
noted, that for both the subcutaneous and glioblastoma models the
MOBILE MR sequence was performed over the entire organ or leg. Thus,
notwithstanding the bright area attributed to subcutaneous fat, other
tissues appear as dark areas in the image sets (Figs. 3b & 4b) and il-
lustrate that the intrinsic lipid content was not high enough to be de-
tected, demonstrating the necessary input of lipid provided by the
LNCs.
4. Discussion
In the present work, the main objective was to demonstrate the
ability of LNCs to probe the oxygen level of normal and tumoural tis-
sues. This was achieved using the MOBILE MR sequence [10] that was
developed to assess oxygenation based on lipid longitudinal relaxation
time. LNCs are excellent for use in tumour therapeutics as they are size
tuneable, can avoid the immune system, have a neutral surface charge,
are formulated with FDA approved constituents which make them
suitable for in vivo administration, and they possess a large lipidic re-
servoir in which lipophilic agents and drugs can be embedded [28,29].
Fig. 3. Application of lipid nanocapsules (LNCs) to assess variations of oxygenation in a subcutaneous FSaII fibrosarcoma tumour mouse model using lipid relaxation
rate measured with the MOBILE MR sequence, wherein (A) shows the transversal anatomical image of a fibrosarcoma tumour and the injected LNCs (indicated by
arrow) and (B) shows the lipid image issued from the set of images acquired with the MOBILE MR sequence wherein the lipids from the LNCs can be observed. The
global R1 measured over the entire lipid deposit signal for all mice (n=7) is shown in (C). The insert in (B) indicates the change in R1 (ΔR1= R1 carbogen – R1 air) for
each pixel of lipid signal in the MOBILE image and a colour scale highlights the more responsive pixels in red (s–1). ΔR1 distribution of all encompassing pixels in the
lipid deposit region of interest is represented as a histogram (D), wherein the median change of R1 is indicated with a dotted red line.
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Thus LNCs, which are already used as a therapeutic nanocarrier
[13,28–31], could also provide oxygenation information of tissues and
double as a diagnostic tool thus becoming a theranostic platform. The
ability of LNCs to respond to variations in oxygen was established using
in vitro conditions wherein the oxygenation environment was con-
trolled. Oxygen level variation accounts for a substantial change in R1
and a linear relationship could be established (Fig. 1); as oxygenation
increased, R1 increased correspondingly. This relationship between the
R1 of lipids found in the LNCs and oxygen content could be reliably
demonstrated and led to in vivo experimentation.
Thus, to further test the ability of the LNCs to probe oxygenation
variation in vivo, a carbogen challenge was performed using three an-
imal tissue models, namely a normal gastrocnemius muscle tissue
model and two tumoural tissue models [32–35]. A bolus injection was
used to introduce the LNC formulation into the muscle tissue, and the
MOBILE MR image after the injection showed that the solution re-
mained as a conglomeration, i.e. as a ‘drop’ (Figs. 2 & 3b). This ‘drop’ of
injected LNCs remained as is for the duration of the experiments and
did not diffuse throughout the tissue. This can be attributed to the di-
rect injection into the tissue; since the LNCs circumvent the washout
and biodistribution associated with an intravenous injection [36–39]
this allows for the formulation's sustained presence within the tissue.
Thus, the persistence of a ‘drop’ of injected LNCs within the tissue is to
be expected, as the normal gastrocnemius muscle is a highly hier-
archized tissue and the bolus injection takes place over a short period of
time, thus not allowing the liquid to disperse throughout the tissue.
Regardless of the dispersion of the injected LNCs in the tissue, the lipids
in the LNCs responded to the carbogen challenge and a map portraying
the variation of the T1 relaxation rate induced by percentage O2 inhaled
could be produced. This map enabled the visualisation of tissue pO2 of
the normal gastrocnemius muscle. Of note, the intrinsic muscular li-
pidic signal is too low to portray the effect of the challenge, thus
making the LNC injection compulsory as no lipid signal can be observed
outside the lipid drop (Fig. 2b). This observation was also noted in the
tumoural models used in this study (Figs. 3 & 4b).
Within the subcutaneous fibrosarcoma tumours, an overall more
limited response to the carbogen challenge was noted; an average R1
increase of 3%, as compared to the 6% from both the gastrocnemius
muscles and intracerebral glioblastomas (Figs. 2–4c). This muted re-
sponse could be attributed to the poor blood perfusion prevalent in this
tumour model [27,40,41], which limits the blood's transportation of the
carbogen gas to the tissue environment near the drop of LNCs.
Fig. 4. Application of lipid nanocapsules (LNCs) to assess variations of oxygenation in a glioblastoma tumour rat model using lipid relaxation rate measured with the
MOBILE MR sequence, wherein (A) shows the transversal anatomical image of a glioblastoma tumour and the injected LNCs (indicated by arrow) and (B) shows the
lipid image issued from the set of images acquired with the MOBILE MR sequence wherein the lipids from the LNCs can be observed. The global R1 measured over the
entire lipid deposit signal for all rats (n= 6) is shown in (C). The insert in (B) indicates the change in R1 (ΔR1=R1 carbogen – R1 air) for each pixel of lipid signal in the
MOBILE image and a colour scale highlights the more responsive pixels in red (s–1). ΔR1 distribution of all encompassing pixels in the lipid deposit region of interest is
represented as a histogram (D), wherein the median change of R1 is indicated with a dotted red line.
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Similarly, this could explain the instance in which the R1 decreased
after the carbogen challenge in an individual animal. On the contrary,
the intracerebral glioblastoma model, is associated with a hetero-
geneous tumour microenvironment which is highly vascularised [26].
This readily explains the increased response of this tumour model,
comparative to the normal gastrocnemius muscle tissue, to the car-
bogen challenge. Furthermore, the methods of LNC introduction be-
tween the two tumour models should be noted. The CED protocol al-
lowed for a more even distribution of the LNCs throughout the brain
tumour tissue, whereas the bolus injection within the muscle and sub-
cutaneous tumour model only allowed for the mapping of the LNCs
within the drop.
Oxygenation mapping within the normal tissue and tumoural
models showed that LNCs were able to improve the lipid signal-to-noise
ratio to such an extent that pixel-to-pixel analysis of the area was
achievable. Therefore, it was possible to image and analyse the re-
sponse of each pixel to the carbogen challenge within all the animal
models without using ionising probes or specialised 19F-based MR
equipment [15,42], thus making our system more widely applicable.
Furthermore, in our study, the bolus injection allowed for a very spe-
cific site within the muscle and subcutaneous fibrosarcoma tumour to
be analysed, whereas the CED diffusion of the LNCs throughout the
intracerebral glioblastoma model allowed for the mapping and analysis
of the entire area of the injected LNCs. Using the pixel-to-pixel analysis,
it was possible to map the heterogeneity of the response from air to
carbogen breathing for each animal (Figs. 2–4c) and the median overall
change of the pixels could be calculated (Figs. 2–4d).
Although mapping of pO2 change in tissue was achievable and
successful, the conversion of R1 to pO2 proved difficult in vivo. Direct
conversion, on the basis of data presented in Fig. 1, of R1 into absolute
pO2 values cannot be done because although R1 has been shown to be
dependent on oxygenation it is also dependant on the heterogeneity of
tissues, viscosity and iron content for example [43–46], all of which are
variables that cannot be easily mimicked in vitro.
5. Conclusion
Herein, our aim was to demonstrate that LNCs, besides its proved
therapeutic nanocarrier efficiency, could be used as a diagnostic tool in
the form of an oxygen sensor for normal and tumoural tissue using the
MOBILE MR sequence. LNCs were synthesised using the phase-inver-
sion process, and the osmolarity of the formulation was adjusted for
safe in vivo use. In vitro validation showed a linear relationship between
oxygen variation and R1, thus demonstrating the permeability and re-
sponsiveness of the LNCs to oxygen. For in vivo experimentation, three
animal models; a normal muscle model and two tumoural tissue models
(subcutaneous fibrosarcoma and intracerebral glioblastoma), were
subjected to a carbogen challenge (95% O2, 5% CO2) to induce tran-
sient oxygenation changes within the tissue. From a single bolus in-
jection of the LNCs, both a global R1 value, as well as a pixel-to-pixel
analysis was possible, due to the improved signal-to-noise provided by
the lipid-core of the LNCs. However, because the bolus injection oc-
curred over a short period of time, a limited area of tissue could be
mapped. Thus, a CED injection was used to diffuse the LNCs throughout
the intracerebral glioblastoma tumours to provide a more detailed
oxygenation and heterogeneity map. Unfortunately, only relative pO2
values were achievable from the LNC system as a myriad of parameters
influence T1 relaxation in vivo. Regardless, these developments and
results indicate that LNCs could be used as both a therapeutic and di-
agnostic tool for cancer.
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